Literature DB >> 20683019

Hypoxia and activated VEGF/receptor pathway in multiple myeloma.

Alexandra Giatromanolaki1, Maria Bai, Dimitrios Margaritis, Konstantinos L Bourantas, Michael I Koukourakis, Efthimios Sivridis, Kevin C Gatter.   

Abstract

BACKGROUND/AIM: Intensified angiogenic pathways are associated with poor prognosis and resistance of multiple myeloma (MM) cells to therapy. The links of the VEGF pathway with the hypoxia inducible factor (HIF) expression in MM are herein investigated.
MATERIALS AND METHODS: The vascular density (VD) and the HIF/VEGF/VEGF-receptor expression in the bone marrows of 106 MM cases were studied using immunohistochemistry.
RESULTS: HIF1alpha and HIF2alpha were expressed strongly in 33% and 13.2% of the cases, respectively. VEGFR and the phosphorylated (active) form of VEGFR2/KDR receptors were up-regulated in 42.5% and 36.8% of cases, respectively. Both HIF1alpha and HIF2alpha were significantly linked with high VD and VEGF expression. Moreover, the expression of the phosphorylated (active) form of VEGFR2/KDR was significantly linked with VEGF and HIF1alpha expression. The HIF/VEGF/VEGF-receptor pathway is up-regulated in approximately 40% of MM cases and linked with increased angiogenesis. Survival analysis in 37 evaluable patients showed a significantly worse prognosis in cases with high VD.
CONCLUSION: HIFs and VEGF are up-regulated in a significant percentage of MM and are strongly related to each other. Targeting HIFs and the VEGF/receptor autocrine loop may prove of importance in the treatment of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20683019

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  30 in total

1.  Adaptation to survival in germinal center is the initial step in onset of indolent stage of multiple myeloma.

Authors:  Ariosto S Silva; Robert A Gatenby
Journal:  Mol Pharm       Date:  2011-10-12       Impact factor: 4.939

2.  Danshen improves damaged cardiac angiogenesis and cardiac function induced by myocardial infarction by modulating HIF1α/VEGFA signaling pathway.

Authors:  Fen Ai; Manhua Chen; Wei Li; Yang Yang; Guizhong Xu; Feng Gui; Zhenxing Liu; Xiangyan Bai; Zhen Chen
Journal:  Int J Clin Exp Med       Date:  2015-10-15

3.  Hypoxia inducible factor-1 alpha and multiple myeloma.

Authors:  Archana Bhaskar; Bhupendra Nath Tiwary
Journal:  Int J Adv Res (Indore)       Date:  2016-01-01

4.  VLA-4 phosphorylation during tumor and immune cell migration relies on its coupling to VEGFR2 and CXCR4 by syndecan-1.

Authors:  Oisun Jung; DeannaLee M Beauvais; Kristin M Adams; Alan C Rapraeger
Journal:  J Cell Sci       Date:  2019-10-28       Impact factor: 5.285

Review 5.  Integration of hypoxic HIF-α signaling in blood cancers.

Authors:  L Schito; S Rey; M Konopleva
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

6.  Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss.

Authors:  Muhammad Zahoor; Marita Westhrin; Kristin Roseth Aass; Siv Helen Moen; Kristine Misund; Katarzyna Maria Psonka-Antonczyk; Mariaserena Giliberto; Glenn Buene; Anders Sundan; Anders Waage; Anne-Marit Sponaas; Therese Standal
Journal:  Blood Adv       Date:  2017-12-13

7.  Hypoxia favors the generation of human plasma cells.

Authors:  Matthieu Schoenhals; Michel Jourdan; Angélique Bruyer; Alboukadel Kassambara; Bernard Klein; Jérôme Moreaux
Journal:  Cell Cycle       Date:  2017-05-02       Impact factor: 4.534

8.  Interrelationship between angiogenesis, inflammation and oxidative stress in Indian patients with multiple myeloma.

Authors:  S Joshi; N Gupta; R Khan; R Kumar; M Sharma; L Kumar; A Sharma
Journal:  Clin Transl Oncol       Date:  2015-07-14       Impact factor: 3.405

9.  Cell Trafficking in Multiple Myeloma.

Authors:  Giada Bianchi; Shaji Kumar; Irene M Ghobrial; Aldo M Roccaro
Journal:  Open J Hematol       Date:  2012-02-21

Review 10.  VEGF targets the tumour cell.

Authors:  Hira Lal Goel; Arthur M Mercurio
Journal:  Nat Rev Cancer       Date:  2013-12       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.